[go: up one dir, main page]

WO1983000293A1 - Stable supersaturated solutions of sparingly soluble salts - Google Patents

Stable supersaturated solutions of sparingly soluble salts Download PDF

Info

Publication number
WO1983000293A1
WO1983000293A1 PCT/US1981/000979 US8100979W WO8300293A1 WO 1983000293 A1 WO1983000293 A1 WO 1983000293A1 US 8100979 W US8100979 W US 8100979W WO 8300293 A1 WO8300293 A1 WO 8300293A1
Authority
WO
WIPO (PCT)
Prior art keywords
salt
solution
polyelectrolyte
sparingly soluble
sodium bicarbonate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1981/000979
Other languages
French (fr)
Inventor
Of Trustees Of Leland Stanford Jr. ... Board
Alan S. Michaels
Michael W. Weiner
Hemant Jalan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to JP50264781A priority Critical patent/JPS58501109A/en
Priority to AU74515/81A priority patent/AU542913B2/en
Priority to EP81902160A priority patent/EP0084024B1/en
Priority to PCT/US1981/000979 priority patent/WO1983000293A1/en
Priority to DE8181902160T priority patent/DE3172710D1/en
Publication of WO1983000293A1 publication Critical patent/WO1983000293A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A61M1/1654Dialysates therefor
    • A61M1/1656Apparatus for preparing dialysates
    • A61M1/1666Apparatus for preparing dialysates by dissolving solids
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F21/00Dissolving
    • B01F21/02Methods
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01DCOMPOUNDS OF ALKALI METALS, i.e. LITHIUM, SODIUM, POTASSIUM, RUBIDIUM, CAESIUM, OR FRANCIUM
    • C01D7/00Carbonates of sodium, potassium or alkali metals in general
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01FMIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F2101/00Mixing characterised by the nature of the mixed materials or by the application field
    • B01F2101/2202Mixing compositions or mixers in the medical or veterinary field

Definitions

  • Anionic functionalities include phosphate, phosphonate, sulfate, sulfonate, and carboxylate. Of particular interest are the weaker acids, such as polyphosphate and polycarboxylate.
  • Various anionic monomers include phosphate, acrylate, maleate, methacrylate, vinyl carboxymethyl ether, or the like. The monomers may be homopolymerized or copolymerized, the organic monomers normally being copolymerized with a wide variety of hydrocarbon or heterosubstituted ethylenic monomers.
  • Specific polyelectrolytes include: 1) Drew 9-041 Drew Chemicals Co. polyacrylic acid ⁇ 2000 mw
  • Acetic acid (glac.) 135 Water to make ⁇ 700ml * KCl could be included in solutions A or B or both
  • membrane filter (0.2 micron) membrane filter (Millipore or equivalent) and transfer to sealable one-liter glass or plastic containers.
  • Solution A can be continuously mixed with water in the required 24:1 ratio, and Solution B metered into this mixture in the desired ratio of 2 ml per liter of dialysate, or
  • concentrates are provided which are stable for long periods of time.
  • Sodium bicarbonate concentrates find particular use in hemodialysis, allowing for the shipment of relatively low volumes of the sodium bicarbonate, which may then be auto matically diluted into a hemodialysis unit to provide for the necessary carbon dioxide concentration.
  • the ticarbonate solutions have long shelf lives. Under conditions which stress the stability of the solutions, the solu tions are stable for extended periods of time.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)

Abstract

Procédé et compositions concernant des solutions aqueuses stables sursaturées de sels inorganiques peu solubles. Le procédé consiste à dépasser le niveau de solubilité d'un sel inorganique peu soluble dans l'eau à des températures ambiantes en présence d'un polyélectrolyte polyanionique ayant un poids moléculaire d'au moins 900 daltons environ et un poids équivalent ionique n'excédant pas 65 environ et au moins cinq groupes ionisables par molécule. Le niveau de solubilité peut être dépassé en refroidissant une solution saturée du sel peu soluble, en préparant le sel peu soluble in situ, ou en ajoutant un sel soluble ayant un ion commun avec le sel peu soluble à une solution concentrée ou saturée du sel peu soluble. La solution aqueuse stable sursaturée de NaHCO3 peut être utilisée pour préparer des solutions d'hémodialyse.Process and compositions relating to stable, supersaturated aqueous solutions of sparingly soluble inorganic salts. The method consists in exceeding the solubility level of an inorganic salt poorly soluble in water at ambient temperatures in the presence of a polyanionic polyelectrolyte having a molecular weight of at least 900 daltons and an equivalent ionic weight not exceeding not about 65 and at least five ionizable groups per molecule. The level of solubility can be exceeded by cooling a saturated solution of the sparingly soluble salt, by preparing the sparingly soluble salt in situ, or by adding a soluble salt having a common ion with the sparingly soluble salt to a concentrated or saturated solution of the sparingly salt soluble. The stable, supersaturated aqueous solution of NaHCO3 can be used to prepare hemodialysis solutions.

Description

STABLE SUPERSATURATED SOLUTIONS OF SPARINGLY SOLUBLE SALTS BACKGROUND OF THE INVENTION Field of the Invention
There are many situations where it is desirable to have a highly concentrated aqueous solution of a sparingly soluble inorganic salt. Such solutions find particular application where a metered addition of the inorganic salt is required within relatively narrow concentration limits, the metered solution being used directly or diluted. An excellent illustration of this situation is a hemodialysis system, where it is desirable to ship the preformed salt solutions at high concentration to minimize the cost of handling and shipment. The hemodialysis unit can then monitor the dilution of the concentrate to provide the necessary salt concentration in the dialysis unit. Other situations where supersaturated aqueous solutions might find use are carbonates in fire extinguishers, preparation of crystals of enhanced size, and in chemical reactions.
Enhanced concentrations of sodium bicarbonate, beyond the solubility limits at ambient temperatures, are of particular interest for hemodialysis. While bicarbonate has always been recognized as the normal physiologic buffer-anion for control of blood pH, its utilization as a component of dialysate in extracorporeal hemodialysis has been confounded by solubility problems peculiar to aqueous solutions of sodium bicarbonate containing other electrolytes required to maintain isotonicity with blood plasma, and by the instability of dissolved hicarhonate to changes in pH and carbon dioxide tension. There has therefore been substantial efforts in this field to develop concentrate solutions which can find acceptance in a hemodialysis unitj while providing the desired high concentration for preparation and shipment. Brief Description of the Prior Art
Van Wager, J. R., "Phosphorus and Its Compounds," Vol. II, Interscience Publishers, New York (1961) gives a general description of utilities for polyphosphates.
SUMMARY OF THE INVENTION Compositions and their method of preparation are provided, wherein the compositions are storage stable supersaturated aqueous solutions of sparingly soluble salts, particularly alkali metal salts. The compositions are prepared in the presence of a polyelectrolyte of at least about 900 daltons, the electrolyte having an ionic equivalent weight of at least about 65 and at least five anionic groups per molecule. The compositions find particular use as concentrates of a source of the inorganic salt, which may be used directly or diluted in a continuous manner to a prede- termined concentration. In addition, the subject compositions find application as enhanced sources of carbon dioxide and as a means for enhancing crystal growth.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS The subject invention provides for the formation of supersaturated solutions of inorganic salts, particularly alkali metal salts, which are sparingly soluble in water. The supersaturated solutions are formed by crossing beyond the saturation point of the sparingly soluble salt in the aqueous medium in the presence of a polyanionic poly electrolyte. Crossing the saturation level to a supersaturated level can be as a result of dissolving the salt at a temperature where it is soluble, preferably at a relatively mildly elevated temperature (usually less than about 65°C) and then cooling the solution past saturation; forming the salt in situ by metathesis or neutralization between an acid and a base, that is, providing the ions of the salt from two different sources; or adding to a solution of the sparingly soluble salt, a more soluble salt having a common ion with the soluble salt. In each instance, a solution of the salt is provided, where the saturation limit of the salt in the solution is exceeded in the presence of a polyanionic polyelectrolyte. The resulting solutions are then stable for long periods of time, particularly storage stable under varying conditions of temperature. Relatively small amounts of the polyelectrolyte are employed.
The sparingly soluble salts are alkali metal, more particularly sodium. The anions will normally be derived from carbonic acid, particularly carbonate and bicarbonate, although other anions which form sparingly soluble salts may also find use. The sparingly soluble salts will generally have a solubility of less than about 10g/100ml at ambient temperature (~20°C). The polyelectrolyte will be at least about 900 daltons, more usually at least about 1,000 daltons, and should be relatively stable under the conditions of formation of the supersaturated solution and on standing. The polyelectrolyte will be water soluble, may be organic or inorganic, and will frequently be a polymer, having a monomer which is singly or doubly charged, particularly a negatively charged (anionic) unit.
Anionic functionalities include phosphate, phosphonate, sulfate, sulfonate, and carboxylate. Of particular interest are the weaker acids, such as polyphosphate and polycarboxylate. Various anionic monomers include phosphate, acrylate, maleate, methacrylate, vinyl carboxymethyl ether, or the like. The monomers may be homopolymerized or copolymerized, the organic monomers normally being copolymerized with a wide variety of hydrocarbon or heterosubstituted ethylenic monomers. The neutral monomers will normally be of from two to six, usually two to four carbon atoms, having from one to three, usually one to two heteroatoms which are oxygen, particularly oxy and oxo, both carbonyl oxo and carboxyl non-oxo-carbonyl .
Illustrative neutral monomers for copolymerization include methyl acrylate, methyl vinyl ether, hydroxyethyl acrylate, ethylene, vinyl acetate, etc. Inorganic polyelectrolytes include polyphosphates, particularly polyphosphates having at least about nine phosphate groups, preferably at least about twelve phosphate groups and less than about 100 phosphate groups, preferably about 20 to 30 phosphate groups.
The charge density or ionic equivalent weight should be less than about 500, usually less than about 400, and generally greater than about 65, usually greater than about 70. The molecular weight of the polyelectrolyte will generally be at least about 900, usually greater than about 1,000, and less than about 500,000, more usually less than about 200,000, preferably from about 10,000 to 100,000.
Specific polyelectrolytes include: 1) Drew 9-041 Drew Chemicals Co. polyacrylic acid ~2000 mw
Colloid X-Hl Stauffer Chem. Co. sulfated cellulose Calgon Stauffer Chem. Co.
Na hexametaphosphate (n=13) Carboxol 94 B. F. Goodrich Co. polyacrylic acid m.w. ~106 Gantrez AN-119 GAF Corp. low mw copolymer of methyl vinyl ether and maleic anhydride Gantrez AN-139 GAF Corp. medium mw copolymer of methyl vinyl ether and maleic anhydride Gantrez AN-163 GAF Corp. high mw copolymer of methyl vinyl ether and maleic anhydride potassium polymetaphosphate n=5K-10K sodium polymetaphosphate n~61
In addition to the sparingly soluble salt, other soluble salts may be present, such as sodium chloride, potassium chloride, lithium chloride, and the like. It should be appreciated, that due to the common ion effect, large amounts of salts which have a common ion with the sparingly soluble salt, will further effect a reduction in the dispersability of the sparingly soluble salt. The amount of the various materials will vary, depending upon the particular salt. Usually, the concen tratioή of the supersaturated sparingly soluble salt will be at least 50% greater than the saturation solubility at ambient temperature, usually at least 100% greater than the saturation solubility at ambient temperature and may be as high as 150% greater or more. The concentration of the polyelectrolyte will be the minimum amount necessary to provide the desired stability, generally being not less than about 0.1g/1., generally ranging from about 0.1 to 5g/l., more usually ranging from about 0.5 to 3g/l. and frequently being from about 0.75 to 2g/l.
Of particular interest are concentrates of sodium bicarbonate for use in hemodialysis units. The solutions will have at least about 20, usually 25 times the concentration required for the hemodialysis unit, generally being at l.east about 0.70eq/l., usually 0.875eq/l., and may be up to leq/1. or greater. The concentration of the polyelectrolyte will be at least about 0.25g/l., usually at least about 0.5g/1, preferably at least about 1g/1., and not exceeding 5g/1., more usually not exceeding 3g/l. In addition to the stabilizing agents and sodium bicarbonate, other salts may be present, particularly sodium chloride, which at 25 fold dilution will be 2.5eq/l. and potassium chloride, at 25meq/l. So far as the weight of the individual materials, the sodium bicarbonate will be about 73.5g/l., the sodium chloride about 146.3g/l. and the potassium chloride about 1.9g/1. The polyelectrolyte will be about 0.75 to 1.5g/l. usually about lg/1. The pH of the solution will generally be from about 8 to 8.5, usually about 8.3. Besides the alkali metal halides, magnesium chloride may also be present, which at 25 fold dilution will be 14meq/l, and about 0.14g/l.
When the bicarbonate concentrate is employed with a separate Ca/Mg concentrate, the Ca/Mg concentrate can provide for the desired pH of the final solution, a pH generally about 7 to 7.5, preferably 7.2. Of particular interest as the polyelectrolyte are the various polyphosphates, particularly sodium hexametaphosphate, potassium polymetaphosphate and sodium polymetaphosphate.
In order to demonstrate the subject invention, sodium bicarbonate solutions for use in a hemodialysis unit were studied as illustrative of the subject invention. Sample solutions were prepared as follows. A stock solution of NaHC03 (0.875g.mol NaHCO3 dissolved in 910ml water to yield 950ml solution) was prepared. To 95ml of the NaHCO- solution was added 0.1g of additive (pH adjusted to within the 7.0-7.5 range if the additive initially exhibited some other pH) followed by the addition of 0.25gm mol NaCl to yield 100ml of a 25X concentrate.
Various polyelectrolytes were employed in preparing solutions in a manner analogous to that described above. Particularly hexaphos, Graham's salt (sodium polymetaphosphate n>61) and Gantrez AN-119.
The phosphate solutions show virtually complete stability to precipitation on ageing at ambient temperature for periods of ca 8 weeks, as well as to cyclic heating and cooling between 4°C and 45°C for periods of up to 5 weeks. Based on earlier experiments Gantrez AN-119 would be expected to perform comparably.
The utilization of the bicarbonate concentrate for hemodialysis was tested by using an in vitro dialysis against a "blood like" salt solution. The following is a description of the materials, the procedure and the results. Materials:
1) Single Batch Bicarbonate Concentrate (25 X) (SBBC)
Wgt. , gm/1 Substance mEq/1 (after dilution)
146.3 NaCl 100 73.5 Na HCOg 35 8.61 Ca Acetate 4 (ideal) 3.0 Xanthan 1.0 Hexaphos 1.88 KCl 1.0
2.55 MgCl2 . 6H2O 1.0
2) Blood-Like Salt Solution ("Blood") Wgt., gm/1 Substance mEq/1
6.72 NaCl 115.0
1.68 NaHC03 20.0 0.166 CaCl2 3.0
Temperature 37°C; bubbled with 5% C02.
3) Cobe Century II AFM Dialysis Control Unit
4) Cordis Dow C-DAK 1.8D Artificial Kidney Methods: Procedure for Dialysis
1) The SBBC was prepared the day of the experiment and used within 6 hours after preparation. The NaCl, NaHCO-, KCl, MgCl, and Hexaphos were dissolved in approximately 800cc of R.O. Water, with continued mixing and slight heating. Xanthan was then homogenized into solution and the volume checked.
(The xanthan was subsequently found to be superfluous and possibly detrimental). The water needed to bring this volume up to 1 liter (~500cc) was used to dissolve the Ca Acetate which was then added to the concentrate under mild homogenation.
2) The Century II was set up in the usual manner, with the substitution of the SBBC for the routine acetate concentrate. The outflowing dialysate was checked for Na concentration after the conductivity reached the proper range (Na+ = 137.4 mEσ/1).
3) The C-DAK 1.8 kidney was connected, flushed and primed with normal saline. 4) The arterial line was connected to the "blood" solution which was kept at a temperature of 37°C. and gassed with 5% CO- to maintain a pC02 of around 30 mmHg. 5) The dialysis was started and the transmembrane pressure (TMP) adjusted to zero. The system was allowed to run undisturbed for ten minutes to allow for stabilization.
6) After the stabilization period, the "blood" outflow (QBo) and the dialysate outflow (QDo) were measured with a timed collection by volume. Samples were collected in the following order: dialysate outflow (Do), "blood" outflow (Bo), dialysate inflow (Di) and "blood" inflow (Bi). The samples were then placed in evacuated glass tubes until analysis. All analysis except total Ca and ortho phosphate were completed within 6 hours of collection.
7) The TMP was changed to -200 mmHg and after a 10 minute stabilization period, the above procedure
(#6) was repeated. Methods: Analytical
1) pH by electrode
2) Total CO2 by Infrared method 3) HCO-3, pC02 calculated from #1 and #2 using the
Henderson-Hasselbach equation
4) Ca +2 (ionic) by electrode (Orion)
5) Ca +2 (total) by atomic absorption (Clinical Lab)
6) Ortho phosphate (H2PO-4) free and total (after 30 minutes of acid hydrolysis at 200°C. to break all linear phosphate polymers to ortho phosphate) was determined using the Fish-Subba-Rew-Summer reaction. Comments: 1. Bicarbonate transfer at a mean of 90mEq/hr. into the patient would be a maximum rate with this size kidney and blood flow. There is a significant drop by approximately 10-15% in bicarbonate transfe the patient when a TMP of -200 mmHg is added. 2. There is a mean net Ca loss of 3.5 mEq/hr. and there seems to be no effect of negative pressure.
This would be a maximum rate of loss. The other complicating factor in Ca +2 transfer is the high pH (8.3) of the returning (post kidney) "blood". With this there is a 20-30% decrease in ionic Ca +2
However, the physiologic effect of this, if any, could only be evaluated in an in vitro system. 3. The total phosphate transfer to the "blood" from the hexaphos in the dialysate is minimal, 0.75 mmols (75 mg) per hour. This number is an artifact since the "blood" in our in vitro system contains no phosphate. The blood of a person with end stage renal disease contains high phosphate levels (0.5 to 1.0 mmols/1) and would result in the net transfer of phosphate from patient to dialysate.
Figure imgf000011_0001
Figure imgf000012_0001
Figure imgf000013_0001
Two solutions could be prepared for use in a hemodialysis unit. One solution "A" would be the sodium bicarbonate concentrate while the other solution "B" would be a Ca/Mg concentrate. The following would be the solution compositions:
"A" g/ 1.
NaHC03 73.5 NaCl 146.3 Hexaphos 1.0 Water to make 12
"B" g/1.
Calcium acetate • H2O 176
MgCl. 6H2O 51
KCl* 37.5
Acetic acid (glac.) 135 Water to make ~700ml * KCl could be included in solutions A or B or both
The preparation of the two solution concentrates is outlined below: A) Solution A (25 x Sodium Bicarbonate/Sodium Chloride Concentrate)—10 Liter Batch
1) Transfer 9.0 liters of distilled, deionized, warm (35°C.) water to a 15-liter stainless steel or glass vessel equipped with a propeller-agitator.
2) Add to (1), with mild agitation, 10.0 grams Hexaphos (Food Grade); when completely dissolved, add 735 grams sodium bicarbonate (C.P. or USP). Continue agitation until solution is clear and no solid remains. 3) With continued mild agitation, slowly sift into the solution of (2) 1463 grams of sodium chloride (USP), allowing sufficient time between successive additions to permit dissolution of the salt. When addition is complete, continue agitation for 10-15 minutes to insure complete solution.
4) Adjust solution-volume to exactly 10 liters by addition of distilled water.
5) Filter the solution by gravity through a qualitative-grade paper filter into a glass carboy, and seal tightly. Allow to stand undisturbed for about 24 hours. Then pres- sure-filter the solution through a sterilizing
(0.2 micron) membrane filter (Millipore or equivalent) and transfer to sealable one-liter glass or plastic containers.
B) Solution B (Acidified Ca/Mg/K Concentrate)—One Liter Batch
1) Place 500 ml of warm (35°C.) distilled, deionized water in a two-liter glass or stainless steel vessel equipped with a propeller-agitator. Add, with gentle stirring, 135 grams of glacial acetic acid.
2) Add consecutively to (1), with mild agitation, 176 grams calcium acetate monohydrate, (USP) 51 grams magnesium chloride hexahydrate, (USP) and 37.5 grams potassium chloride (USP). Continue agitation until solution is clear, and then bring volume to exactly 1.0 liter with distilled water.
3) Filter the solution through a qualitative grade paper filter into a glass bottle, and seal tightly. Allow to stand undisturbed for about 24 hours. Then pressure-filter the solution through a sterilizing (0.2 micron) .. membrane filter, and transfer to sealable 50 ml glass vials.
The process of combining Solution A (1 liter). Solution B (50 ml), and water (24 liters) to yield 25 liters of dialysate of proper composition can be accomplished by two alternative procedures:
1) Solution A can be continuously mixed with water in the required 24:1 ratio, and Solution B metered into this mixture in the desired ratio of 2 ml per liter of dialysate, or
2) Solution B can be continuously mixed with water in the ratio of 1 ml/4.8 liters water, and this solution then mixed continuously with Solution A in the desired ratio of 1 liter A per 24 liters water/B mixture.
Of the two alternatives proposed, the second is to be preferred for two principal reasons: Firstly, predilution of the acidic B-concentrate with water will eliminate local large excursion in pH and calcium-ion concentration due to mixing-inhomogeneities, and thus minimize the likelihood of CO2-loss and calcium carbonate precipitation. Secondly, automatic conductivity-control of the mixing ratio of Solution A and the Water/B premix will be quite sensitive and accurate, since the contribution of the ionic components of Solution B to the total conductivity of the final diluted dialysate is very small; hence, the precision of the mixing ratio of Solution A with the bulk of the dialysate (if con trolled by conductivity) will be high irrespective of varia tions in the ratio of B to water in the premix. Thus the existing delivery system provided by the commercially available Cobe Century II unit is adequate for the delivery of fully-constituted bicarbonate dialysate, with a means (either by incorporation within or addition to the system) for volumetrically metering Solution B into the water fed to the system, in a roughly 1:5000 ratio. This could be accomplished, for example, by (1) delivering B-concentrate via a motor-driven syringe-pump through a capillary-tubing feed-line to the water-supply inlet; or (2) ganging water and concentrate-tubing pumps together via a common drive an gear-reduction train, so that the ratio of volumetric deliveries of the two fluids is maintained at the desired value. Other techniques of metering the fluid at a very low flow rate into another flowing at a much higher rate may also be feasible. High precision in control of the mixing ratio of Solution B with feed-water is not required, since the only component-concentrations in the final dialysate which depend on this ratio are the minor components: calcium, magnesium, potassium, and hydrogen ion. Moreover, because of the strong buffering capacity of the bicarbonate present in solution, the pH of the final dialysate will be quite insensitive to variations in the amount of acid added. For example, doubling the mixing ratio of Solution B to water would cause the Ca++ ion concentration to rise from 4.0 to 8.0 mEq/1, Mg++ and K+ from 1.0 to 2.0 mEq/1, and the pH to drop from 7.2 to 6.9. Thus, even a 50 percent variability in the mixing ratio would yield a final dialysate of physiologically acceptable composition, with little to no attendant risk to the patient..
In accordance with the subject invention, concentrates are provided which are stable for long periods of time. Sodium bicarbonate concentrates find particular use in hemodialysis, allowing for the shipment of relatively low volumes of the sodium bicarbonate, which may then be auto matically diluted into a hemodialysis unit to provide for the necessary carbon dioxide concentration. Furthermore, the ticarbonate solutions have long shelf lives. Under conditions which stress the stability of the solutions, the solu tions are stable for extended periods of time.
In addition, the subject invention, provides a convenient method for preparing stable supersaturated solutions by using either a single or combination of reagents which inhibit the precipitation of solids. Alternatively, one can provide for highly supersaturated solutions of salts, so as to modify the crystal properties of a precipitate.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A method for preparing supersaturated aqueous solutions of sparingly soluble inorganic salts of alkali metals, said method comprising: forming a supersaturated solution of said sparingly soluble inorganic salt in an aqueous medium, wherein the saturation limit of said salt is exceeded in said aqueous medium in the presence of a polyanionic polyelectrolyte present-in said solution in sufficient amount to stabilize said sparingly soluble salt in solution, said polyelectrolyte being of at least about 900 daltons and having at least five ionizable groups.
2. A method according to Claim 1, wherein said polyelectrolyte is present in from about 0.5 to 5g/l.
3. A method according to Claim 2, wherein said polyelectrolyte is a polyphosphate.
4. A method according to Claim 2, wherein said polyelectrolyte is a polycarboxylate.
5. A method according to Claim 1, wherein said salt is dissolved at an elevated temperature, and said saturation limit of said salt is exceeded by cooling.
6. A method according to Claim 1, wherein said salt is prepared in situ.
7. A method according to Claim 1, wherein said saturation limit of said salt is exceeded by the addition of a soluble salt having a common ion with said sparingly soluble salt.
8. A method for preparing a sodium bicarbonate concentrate, said method comprising: dissolving sodium bicarbonate in water in an amount greater than at least about 50% greater than the saturation solubility at ambient temperature of said sodium bicarbonate in the presence of a polyelectrolyte at a concentration in the range of about 0.5 to 5g/l., said polyelectrolyte having a molecular weight of at least about 900 daltons and having at least five ionizable groups to provide negative charges.
9. A method according to Claim 5, which includes the step of dissolving sodium chloride in said solution.
10. A method according to any of Claims 5 or 6, wherein said polyelectrolyte is a polyphosphate having at least nine phosphate groups.
11. A method according to any of Claims 5 or 6, wherein said polyelectrolyte is an addition polymer polycarboxylate.
12. An aqueous composition comprising from about 0.875 equivalents per liter to about one equivalent per.liter of sodium bicarbonate and from about 0.7g/l. to about 3 g/1. of a polyphosphate.
13. A composition according to Claim 12,having about 0.875 equivalents per liter of sodium bicarbonate, about 146.3g/l of sodium chloride and up to 1.9g/l of potassium chloride.
14. In a method for the hemodialysis of blood, the improvement which comprises employing as a source of sodium bicarbonate, a composition according to Claim 12 and diluting said composition in combination with a source of calcium and magnesium to provide a physiological composition for hemodialysis.
15. A method for preparing a solution for a hemodialysis unit which comprises combining a sodium bicarbonate concentrate prepared according to claim 5 or 6 with water and an aqueous solution of chlorides of calcium and magnesium to provide a hemodialysis solution having the desired concentration of bicarbonate, calcium and magnesium.
PCT/US1981/000979 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts Ceased WO1983000293A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50264781A JPS58501109A (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of finitely soluble salts
AU74515/81A AU542913B2 (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts
EP81902160A EP0084024B1 (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts
PCT/US1981/000979 WO1983000293A1 (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts
DE8181902160T DE3172710D1 (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1981/000979 WO1983000293A1 (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts

Publications (1)

Publication Number Publication Date
WO1983000293A1 true WO1983000293A1 (en) 1983-02-03

Family

ID=22161330

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1981/000979 Ceased WO1983000293A1 (en) 1981-07-21 1981-07-21 Stable supersaturated solutions of sparingly soluble salts

Country Status (5)

Country Link
EP (1) EP0084024B1 (en)
JP (1) JPS58501109A (en)
AU (1) AU542913B2 (en)
DE (1) DE3172710D1 (en)
WO (1) WO1983000293A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347521A1 (en) * 1983-11-09 1985-05-30 Fritz 8000 München Marschall Multi-purpose vehicle
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US6696420B1 (en) 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
WO2009044919A1 (en) * 2007-10-05 2009-04-09 National University Corporation Chiba University Stable bicarbonate ion-containing drug solution
US9161980B2 (en) 2004-03-01 2015-10-20 Gambro Lundia Ab Medical solution, a method for producing said medical solution and use thereof
WO2020133198A1 (en) * 2018-12-28 2020-07-02 Fresenius Medical Care R&D (Shanghai) Co., Ltd. Stabilized aqueous hemofiltration basic solution, dialysis solution and corresponding kit
US10729721B2 (en) 2004-10-14 2020-08-04 Gambro Lundia Ab Dialysis solution, formulated and stored in two parts, comprising phosphate
CN115323196A (en) * 2015-01-27 2022-11-11 里德先进材料有限公司 Processing of Lithium-Containing Materials Including HCl Ejection

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108992460A (en) * 2018-08-31 2018-12-14 山东威高药业股份有限公司 A kind of preparation process of haemodialysis concentration B liquid

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560380A (en) * 1968-10-28 1971-02-02 Mallinckrodt Chemical Works Dry concentrates for preparing hemodialysis solutions
US3962075A (en) * 1973-09-10 1976-06-08 Tri-Flo Research Laboratories, Ltd. Hemo dialyzer employing two dialysate solutions
US4075108A (en) * 1974-03-26 1978-02-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Polycarbonate membranes and production thereof
US4202760A (en) * 1978-07-24 1980-05-13 Cordis Dow Corp. Apparatus and method for preparation of a hemodialysis solution optionally containing bicarbonate

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560380A (en) * 1968-10-28 1971-02-02 Mallinckrodt Chemical Works Dry concentrates for preparing hemodialysis solutions
US3962075A (en) * 1973-09-10 1976-06-08 Tri-Flo Research Laboratories, Ltd. Hemo dialyzer employing two dialysate solutions
US4075108A (en) * 1974-03-26 1978-02-21 The United States Of America As Represented By The Department Of Health, Education And Welfare Polycarbonate membranes and production thereof
US4202760A (en) * 1978-07-24 1980-05-13 Cordis Dow Corp. Apparatus and method for preparation of a hemodialysis solution optionally containing bicarbonate

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3347521A1 (en) * 1983-11-09 1985-05-30 Fritz 8000 München Marschall Multi-purpose vehicle
US6696420B1 (en) 1984-11-20 2004-02-24 Institut Pasteur Adenoviral vector with a deletion in the E1A coding region expressing a hetorologous protein
US5068192A (en) * 1986-01-27 1991-11-26 Prutech Research And Development Partnership Attenuated pseudorabies virus which includes foreign DNA encoding an amino acid sequence
US9161980B2 (en) 2004-03-01 2015-10-20 Gambro Lundia Ab Medical solution, a method for producing said medical solution and use thereof
US11285173B2 (en) 2004-10-14 2022-03-29 Gambro Lundia Ab Dialysis solution, formulated and stored in two parts, comprising phosphate
US10729722B2 (en) 2004-10-14 2020-08-04 Gambro Lundia Ab Dialysis solution, formulated and stored in two parts, comprising phosphate
US10729721B2 (en) 2004-10-14 2020-08-04 Gambro Lundia Ab Dialysis solution, formulated and stored in two parts, comprising phosphate
US8771749B2 (en) 2007-10-05 2014-07-08 National University Corporation Chiba University Stable bicarbonate ion-containing drug solution
US9795636B2 (en) 2007-10-05 2017-10-24 National University Corporation Chiba University Stable bicarbonate ion-containing drug solution
CN101888846B (en) * 2007-10-05 2013-02-27 国立大学法人千叶大学 Stable drug solution containing bicarbonate ions
AU2008307966B2 (en) * 2007-10-05 2011-09-29 Fuso Pharmaceutical Industries, Ltd. Stable bicarbonate ion-containing drug solution
WO2009044919A1 (en) * 2007-10-05 2009-04-09 National University Corporation Chiba University Stable bicarbonate ion-containing drug solution
CN115323196A (en) * 2015-01-27 2022-11-11 里德先进材料有限公司 Processing of Lithium-Containing Materials Including HCl Ejection
WO2020133198A1 (en) * 2018-12-28 2020-07-02 Fresenius Medical Care R&D (Shanghai) Co., Ltd. Stabilized aqueous hemofiltration basic solution, dialysis solution and corresponding kit

Also Published As

Publication number Publication date
EP0084024B1 (en) 1985-10-23
AU542913B2 (en) 1985-03-21
DE3172710D1 (en) 1985-11-28
AU7451581A (en) 1983-03-17
EP0084024A4 (en) 1983-12-01
EP0084024A1 (en) 1983-07-27
JPS58501109A (en) 1983-07-14

Similar Documents

Publication Publication Date Title
US4489535A (en) Materials and method for preparing dialysis solutions containing bicarbonate ions
US6475529B2 (en) Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy
Turnberg et al. Mechanism of bicarbonate absorption and its relationship to sodium transport in the human jejunum
AU2002356899B2 (en) Bicarbonate-based solutions for dialysis therapies
US20040121982A1 (en) Biocompatible dialysis fluids containing icodextrins
EP0084024B1 (en) Stable supersaturated solutions of sparingly soluble salts
JP2006056873A (en) Chemical preparation for dialysis using citrate salt as base
CA1166966A (en) System for bicarbonate dialysate
JP2000288083A (en) Solution, more particularly solution for blood dialysis or peritoneal dialysis and its preparation
TWI240630B (en) Buffered compositions for dialysis
BR112012023623B1 (en) Solution for use in dialysis
DK1354607T4 (en) Solution for peritoneal dialysis and double chamber bag for same
Henderson et al. Influence of antidiuretic hormone on peritoneal membrane area and permeability
US4292227A (en) Stable supersaturated solutions of sparingly soluble salts
ES2598031T3 (en) Pharmaceutical compositions containing carboxylated starch
Stern et al. Effect of cortical-medullary gradient for ammonia on urinary excretion of ammonia
CA1180279A (en) Stable supersaturated solutions of sparingly soluble salts
JPH02304026A (en) Liquid for peritoneal lavage
EP1890686A1 (en) Peritoneal dialysis fluid
Eknoyan et al. Chronic hydronephrosis: observations on the mechanism of the defect in urine concentration
NL8103977A (en) Stable supersaturated solns. of sparingly soluble salts - formed in the presence of polyanionic polyelectrolyte of at least 900 daltons
Siegel et al. Potassium and sodium excretion and potassium homeostasis during acute hypokalemia
CA1304688C (en) Fluid therapy with 1-lactate and/or pyruvate anions
AU2008201009B2 (en) Bicarbonate-based solutions for dialysis therapies
YAMADA et al. The effect of polycarbophil on water transport in rat intestine

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU JP

AL Designated countries for regional patents

Designated state(s): AT CH DE FR GB LU SE

WWE Wipo information: entry into national phase

Ref document number: 1981902160

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1981902160

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1981902160

Country of ref document: EP